Inventiva Logo

Inventiva

Clinical-stage biopharma developing oral therapies for fibrosis, oncology, & lysosomal disorders.

IVA | PA

Overview

Corporate Details

ISIN(s):
FR0013233012 (+2 more)
LEI:
969500I9Y690B3FZW590
Country:
France
Address:
50 RUE DE DIJON, 21121 DAIX
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Inventiva is a clinical-stage biopharmaceutical company focused on the development of novel oral small molecule therapies for diseases with significant unmet medical needs. The company's primary therapeutic areas include fibrosis, lysosomal storage disorders, and oncology. Its lead drug candidate, lanifibranor, is in a pivotal Phase III clinical trial for the treatment of non-alcoholic steatohepatitis (NASH) and has received Breakthrough Therapy Designation from the FDA. Another clinical candidate, odiparcil, targets mucopolysaccharidoses (MPS). Inventiva's pipeline is supported by a proprietary discovery engine with an extensive library of 240,000 compounds, a wholly-owned R&D facility, and expertise in targeting nuclear receptors and transcription factors.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:56
Regulatory News Service
Franchissement de seuils
French 120.1 KB
2025-11-28 15:42
Major Shareholding Notification
Franchissement de seuils
French 121.1 KB
2025-11-28 15:25
Major Shareholding Notification
Franchissement de seuils
French 110.0 KB
2025-11-13 15:21
ISS
Inventiva annonce les modalités définitives ainsi que l'extension de l'offre au…
French 353.4 KB
2025-11-13 15:21
ISS
Inventiva announces pricing of upsized public offering of approximately $150M o…
English 349.5 KB
2025-09-29 00:00
Interim Report
RFS
French 927.7 KB
2025-08-25 09:57
Major Shareholding Notification
Franchissement de seuil
French 114.0 KB
2025-08-25 09:56
Major Shareholding Notification
Franchissement de seuil
French 112.0 KB
2025-08-19 15:35
Major Shareholding Notification
Franchissement de seuil
French 116.8 KB
2025-08-19 15:32
Major Shareholding Notification
Franchissement de seuil
French 116.7 KB
2025-08-19 15:19
Major Shareholding Notification
Franchissement de seuil
French 116.1 KB
2025-08-12 15:57
Major Shareholding Notification
Franchissement de seuil
French 113.9 KB
2025-08-12 15:52
Major Shareholding Notification
Franchissements de seuil
French 121.6 KB
2025-08-11 15:14
Major Shareholding Notification
Franchissement de seuil
French 121.9 KB
2025-06-17 17:02
Major Shareholding Notification
Franchissement de seuils
French 113.4 KB

Automate Your Workflow. Get a real-time feed of all Inventiva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Inventiva

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Inventiva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-04-05 N/A Other Buy 10,000 N/A
2023-12-08 N/A Other Buy 15,000 N/A

Peer Companies

Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xilio Therapeutics, Inc. Logo
Engineering tumor-activated biologics for cancer to maximize efficacy and minimize toxicity.
United States of America
XLO
XLMEDIA PLC Logo
A former performance marketing company for the sports and gaming industries.
Jersey
XLM
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xplus Inc. Logo
IT consultancy guiding digital transformation via enterprise architecture & program management.
South Korea
373200
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB
YAMADA Consulting Group  CO.,LTD. Logo
Japanese consulting firm offering global M&A, strategy, and financial advisory services.
Japan
4792
Y-Biologics, Inc Logo
Develops novel antibody cancer therapies using proprietary T-cell engager & antibody library tech.
South Korea
338840
Yellow Balloon Tour Co., Ltd. Logo
Offers domestic & international travel packages, flights, and tours for individuals and groups.
South Korea
104620
Yoshimura Food Holdings K.K. Logo
Acquires and revitalizes Japanese food SMEs via a support platform for global expansion.
Japan
2884

Talk to a Data Expert

Have a question? We'll get back to you promptly.